Conceptos Categóricos

NORMAS PARA CONTROL Y SEGUIMIENTO DE NIÑOS CON DISPLASIA BRONCOPULMONAR (ENFERMEDAD PULMONAR CRONICA DE LA INFANCIA)

NORMAS PARA CONTROL Y SEGUIMIENTO DE NIÑOS CON DISPLASIA BRONCOPULMONAR (ENFERMEDAD PULMONAR CRONICA DE LA INFANCIA)

(especial para SIIC © Derechos reservados)
Para un adecuado control y seguimiento multidisciplinar, abordamos esta patología con el objetivo de elaborar un plan de actuación cuando estos neonatos se encuentran en casa tras el alta hospitalaria.
salcedoposadas9.jpg Autor:
Antonio Salcedo Posadas
Columnista Experto de SIIC

Institución:
Hospital General Universitario Gregorio Marañón


Artículos publicados por Antonio Salcedo Posadas
Coautores
Raquel Herráiz* Esther González** Juan Luis Rodriguez Cimadevilla*** 
Licenciado en Medicina y Cirugía. Especialista en Pediatría, Hospital General Universitario Gregorio Marañón, Madrid, España*
Licenciada en Medicina y Cirugía. Especialista en Pediatría, Hospital General Universitario Gregorio Marañón, Madrid, España**
Licenciado en Medicina y Cirugía. Especialista en Neumología Pediátrica, Hospital General Universitario Gregorio Marañón, Madrid, España***
Recepción del artículo
17 de Junio, 2014
Aprobación
25 de Agosto, 2014
Primera edición
29 de Septiembre, 2014
Segunda edición, ampliada y corregida
5 de Febrero, 2015

Resumen
La displasia broncopulmonar (enfermedad pulmonar crónica de la infancia) constituye un grupo heterogéneo de enfermedades de etiopatogenia multifactorial y fisiopatología multisistémica. Su frecuencia ha aumentado en los últimos años debido principalmente a la mayor supervivencia de los recién nacidos prematuros de muy bajo peso al nacer que presentan interrupción del desarrollo vascular y pulmonar unido a alteraciones funcionales generadas por el déficit de surfactante y relacionadas con la inmadurez. Sin embargo, se ha controlado la gravedad de estas patologías gracias a los cambios realizados en la práctica clínica. Para un adecuado control y seguimiento multidisciplinario, abordamos esta patología con el objetivo de elaborar un plan de actuación cuando estos neonatos se encuentran en su hogar tras el alta hospitalaria.

Palabras clave
displasia broncopulmonar, enfermedad pulmonar crónica de la infancia, prematuridad, prevención


Artículo completo

(castellano)
Extensión:  +/-8.15 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Bronchopulmonary dysplasia (chronic lung disease in infants) constitutes a heterogeneous group of diseases with multifactorial etiology and pathogenesis. In recent years, the frequency has increased due mainly to improved survival of newborns of very low weight. In recent years, the frequency of this disease has risen mainly because of the increased survival of very low birth weight preterm neonates with disruption of vascular and lung development linked to functional alterations related to surfactant deficiency and immaturity. The severity of these disorders, however, has been modulated by changes in clinical practice. To achieve the necessary control, and for a multidisciplinary follow-up, we will be addressing this disease with the objective of elaborating a performance plan when these newborns are at home after being discharged.

Key words
bronchopulmonary displasia, chronic lung disease of infancy, prematurity, prevention


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neumonología, Pediatría
Relacionadas: Medicina Familiar



Comprar este artículo
Extensión: 8.15 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Antonio Salcedo Posadas, Hospital General Universitario Gregorio Marañón, 28009, C/ Dr. Castelo, 47, Madrid, España
Bibliografía del artículo
1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116:1353-60, 2005.
2. Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Semin Neonatol 8:117-26, 2003.
3. Sánchez Luna M, Moreno Hernando J, Botet Mussonsa F, Fernández Lorenzo JR, Herranz Carrillo G, Rite Gracia S, et al. Displasia broncopulmonar: definiciones y clasificación. An Pediatr (Barc) 79(4):262.e1-262.e6, 2013.
4. Hayes D Jr, Feola DJ, Murphy BS, Shook LA, Ballard HO. Pathogenesis of bronchopulmonary dysplasia. Respiration 79:425-36, 2010.
5. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 8:63-71, 2003.
6. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary displasia. Lancet 367:1421-31, 2006.
7. Carlton DP, Albertine KH, Cho SC, Lont M, Bland RD. Role of neutrophils in lung vascular injury and edema after premature birth in lambs. J Appl Physiol 83:1307-17, 1997.
8. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 93:712-8, 1994.
9. Cassell GH, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very low- birth-weight infants. Lancet 2:240-5, 1988.
10. Jonsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr 87:1079-84, 1998.
11. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for theprevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev (4):CD003744, 2003.
12. Sawyer MH, Edwards DK, Spector SA. Cytomegalovirus infection and bronchopulmonary dysplasia in premature infants. Am J Dis Child 141:303-5, 1987.
13. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 143:713-9, 2003.
14. Watts JL, Milner R, Zipursky A, Paes B, Ling E, Gill G, et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. Eur Respir J 4:188-90, 1991.
15. Rova M, Haataja R, Marttila R, Ollikainen V, Tammela O, Hallman M. Data mining and multiparameter analysis of lung surfactant protein genes in bronchopulmonary dysplasia. Hum Mol Genet 13:1095-104, 2004.
16. Parton LA, Strassberg SS, Qian D, Galván-Parton PA, Cristea IA. The genetic basis for bronchopulmonary dysplasia. Front Biosci 11:1854-60, 2006.
17. Clark H, Clark LS. The genetics of neonatal respiratory disease. Semin Fetal Neonatal Med 10:271-82, 2005.
18. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340:1962-8, 1999.
19. Gaynor EB, Danoff SF. The role of gentle ventilation in prevention of subglotic stenosis in newborn. Otolaryngol Head Neck Surg 109:701-6, 1993.
20. Nagaraj HS, Shott R, Fellows R, Yacoub U. Recurrent lobar atelectasis due to acquired bronchial stenosis in neonates. J Pediatr Surg 15:411-5, 1980.
21. Farquhar M, Fitzgerald DA. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev 11:149-53, 2010.
22. Narendra A, White MP, Rolton HA, Alloub ZI, Wilkinson G, McColl JH, Beattle J. Nephrocalcinosis in preterm babies. Arch Dis Child Fetal Neonatal 85:F207-13, 2001.
23. Schulzke SM, Pillow JJ. The management of evolving bronchopulmonary dysplasia. Paediatr Respir Rev 11:143-8, 2010.
24. Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD001146. DOI: 10.1002/14651858.CD001146.pub4.
25. Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD001145. DOI: 10.1002/14651858.CD001145.pub3.
26. Jobe AH. The new bronchopulmonary dysplasia. Current Opinion in Pediatrics 23:167-72, 2011.
27. Fitzgerald DA, Van Asperen PP, Lam AH, De Silva M, Henderson-Smart DJ. Chest radiograph abnormalities in very low birth weight survivors of chronic neonatal lung disease. J Paediatr Child Health 32:491-4, 1996.
28. Wilson AC. What does imaging the chest tell us about bronchopulmonary dysplasia? Paediatr Respir Rev 11:158-61, 2010.
29. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, et al; American Thoracic Society. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 168:356-96, 2003.
30. Gappa M, Pillow JJ, Allen J, Mayer O, Stocks J. Lung function tests in neonates and infants with chronic lung disease: lung and chest-wall mechanics. Pediatr Pulmonol 41:291-317, 2006.
31. Allen JL, Panitch HB. Lung function testing: chronic lung disease of infancy. Pediatr Pulmonol 23:138-40, 2001.
32. Greenough A. Bronchopulmonary dysplasia. Long term follow up. Paediatr Respir Rev 7:189-91, 2006.
33. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia: current issues. Pediatr Clin North Am 41:277-315, 1994.
34. Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blindstudy. Eur J Pediatr 157:926-31, 1998.
35. Greenough A, Alexander J, Burgess S, Chetcuti PAJ, Cox S, Lenney W, et al. Home oxygen status on rehospitalisation and primary care requirements of chroniclung disease infants. Arch Dis Child 86:40-3, 2002.
36. Greenough A, Alexander J, Burgess S, Bytham J, Checuti PAJ, Hagan J, et al. Preschool health care utilisation related to home oxygen status. Arch Dis Child Fetal Neonatal Ed 91:F337-F341, 2006.
37. Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, Greenough A. Prospective study of health care utilisation and respiratory morbiditydue to RSV infection in prematurely born infants. Thorax 60:1039-44, 2005.
38. Greenough A. Long-term pulmonary outcome in the preterm infant. Neonatology 93:324-7, 2008.
39. Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30:200-8, 2006.
40. Rüdiger M, Von Baehr A, Haupt R, Wauer RR, Rüstow B. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 28:1572-7, 2000.
41. Simmer K, Rao SC. Early introduction of lipids to parenterally-fed preterm infants. Cochrane Database Syst Rev (2):CD005256, 2005.
42. Saigal S, Stokopf BL, Streiner DL, Burrows E. Physical growth and current health status of infants who were of extremely low birth weight and controls at adolescence. Pediatrics 108:407-15, 2001.
43. Ford GW, Doyle LW, Davis NM, Callanan C. Very low birth weight and growth into adolescence. Arch Pediatr Adolesc Med 154:778-84, 2000.
44. Doyle LW, Anderson PJ. Long-term outcomes of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 14:391-5, 2009.
45. Karagianni P, Tsakalidis C, Kyriakidou M, Mitsiakos G, Chatziioanidis H, Porpodi M, et al. Neuromotor outcomes in infants with bronchopulmonary dysplasia. Pediatr Neurol 44:40-6, 2011.

 
 
 
 
 
 
Clasificado en
Artículos originales>
Expertos del Mundo

Especialidad principal:
Neumonología
Pediatría


Relacionadas:
Medicina Familiar
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618